Febico Biomedical Corp.
1 clinical trials · Sponsor
◉ Watch Febico Biomedical Corp.
| Record | Firm | Date |
|---|---|---|
| To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization (NCT06478719) | Febico Biomedical Corp. | 2024-06-24 |
Track Febico Biomedical Corp. automatically
Every clearance here is in the API, with alerts when new ones post.